(CRDF) Cardiff Oncology, Inc. Porters Five Forces Research

Cardiff Oncology, Inc. faces high supplier power because its vendors must meet FDA and cGMP rules, which sharply limits the pool of qualified manufacturers and testing labs. That means Cardiff Oncology, Inc. cannot simply switch to a cheaper supplier without risking batch failures, delays, or a compliance problem that could block clinical supply.

For a clinical-stage biotech like Cardiff Oncology, Inc., supplier relationships are strategic because a single quality lapse can stall trials and raise cash burn. In practical terms, this makes low-cost bargaining weaker than compliance and continuity.

• FDA and cGMP standards narrow vendor choice.
• Low-cost switching can create compliance risk.
• Quality failures can delay trial supply.
• Supplier ties are strategically important.

Biotech suppliers do more than sell inputs; they often add process development and analytical work that clinical-stage programs need. In 2025, outsourced development and manufacturing still handled a large share of biotech work, so switching a specialist supplier can slow timelines and raise costs.

For Cardiff Oncology, Inc., that gives key suppliers real leverage over speed, execution quality, and spend. If a supplier owns a validated assay or process step, replacing that know-how mid-program can delay milestones by months.

• Specialist support is hard to replace fast.
• Supplier know-how can delay clinical work.
• Costs rise when switching is forced.

Physicians set a high bar: they follow evidence-based guidelines and proven standard-of-care regimens, so Cardiff Oncology, Inc. only wins share if its data beat existing options. With no approved product and no sales in 2025, customer acceptance depends almost entirely on trial readouts, not marketing. If the clinical benefit is modest, oncologists will stay with standard regimens like FOLFOX and FOLFIRI.

• Guidelines drive prescribing.
• Trial wins drive switching.
• No clear edge, no adoption.

Cancer patients rarely negotiate price or terms directly; choice is filtered by oncologists, hospitals, and payers. That keeps Cardiff Oncology, Inc.’s customer power moderate, not high.

Demand can still shift fast if clinicians see weak outcomes or no clear advantage versus existing regimens, because advocacy groups and second opinions matter. In U.S. oncology, access is already shaped by prior authorization and formulary rules, so differentiation is the real lever.

• Patients choose less than physicians and payers
• Access depends on coverage and hospital use
• Weak clinical data raises customer power

Big pharma can run many oncology programs at once, pay for global trials, and move faster on site setup, so Cardiff Oncology faces a much higher proof-of-concept bar. Large peers also buy promising assets outright, and oncology M&A has stayed active with multi-billion-dollar deals, which keeps pressure on small caps. That means Cardiff must show strong data early, before bigger rivals crowd the field.

• More capital, more trials, faster execution
• Acquisition risk raises rivalry pressure
• Early data must be clear and strong

Fast innovation cycles keep rivalry high for Cardiff Oncology, Inc. In colorectal cancer, prostate cancer, and leukemia, new data and combo regimens can change the field fast, with global annual cases near 1.9 million, 1.5 million, and 0.5 million, respectively. If Cardiff Oncology slips on readouts, better data from rivals can quickly reset the benchmark.

• High trial pace raises replacement risk
• Better data can win physician attention
• Delays can weaken pricing power

Oncologists can swap out one drug in a regimen if it underperforms or drives toxicity, so combination therapy is a real substitute threat for Cardiff Oncology, Inc.. In metastatic colorectal cancer, 90%+ of patients already receive multi-drug regimens, which makes it easy to replace a weak link and weakens demand lock-in.

Cardiff Oncology, Inc. must show clear added benefit, such as better response or lower toxicity, to stay in the regimen. If the incremental gain is small, physicians can move to another agent fast.

• Easy regimen switching
• High combo use in CRC
• Incremental benefit is critical

Non-drug options keep the substitution threat high for Cardiff Oncology, Inc., because surgery, radiation, and supportive care can be preferred first in some settings. In localized disease, curative surgery or radiation can delay or replace a new systemic drug, especially when tumor control is the main goal. The wider the treatment menu, the more easily clinicians can switch away from a new oncology therapy.

• Stage and intent drive substitution.
• Local therapy can come first.
• Supportive care can replace escalation.

Successful entry into PLK biology and combination oncology needs rare scientific depth, and that barrier keeps new rivals out. Biotech drug development still has a near 10% success rate from Phase 1 to approval, so newcomers must win both data and trust before they can compete. Recruiting this caliber of clinical and translational talent takes time, which slows entry.

• Deep PLK expertise is hard to hire.
• Credibility takes years, not months.
• High failure rates deter fast entry.

New entrants still need CROs, trial sites, and investors to trust the program before scale-up. Cardiff Oncology’s lead asset, onvansertib, has already been tested in 5 clinical studies, and that history helps lower skepticism and speed site adoption.

In 2024, Cardiff Oncology held about $41.5 million in cash and equivalents, showing how much capital even a small entrant needs to stay credible. So entry is possible, but it is slow, partnership-heavy, and expensive.

• Trust takes data and time.
• Incumbents start with an edge.